Benign Prostatic Hyperplasia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Increased Plasmatic Levels of PSA-Expressing Exosomes Distinguish Prostate Cancer Patients from Benign Prostatic Hyperplasia: A Prospective Study.
|
31569672 |
2019 |
Benign Prostatic Hyperplasia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Here, we described an Italian pedigree affected by HHL but also prostate hyperplasia and increased ratio of the free/total PSA levels, with the unusual and extremely rare Y-linked pattern of inheritance.
|
30341416 |
2019 |
Benign Prostatic Hyperplasia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We first profiled global serum miRNAs in a pilot set of PCa and benign prostatic hyperplasia (BPH) cases undergoing TRUS-guided prostate biopsy due to elevated PSA levels.
|
31534967 |
2019 |
Benign Prostatic Hyperplasia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In addition, the PSA levels were correlated with the expression of DRD1 in BPH cases and DRD1, DRD4, DRD5, and IL6 in PCa cases.
|
31288722 |
2019 |
Benign Prostatic Hyperplasia
|
0.100 |
Biomarker
|
disease |
BEFREE |
In patients with PSA ≤20 ng/ml, T/PSA was higher in those with BPH than in those with PCa (4.69 versus 2.24; p < .001).
|
28752596 |
2018 |
Benign Prostatic Hyperplasia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
PSA level was significantly higher in the PCa group than in BPH (18.2 versus 9 ng/mL, <i>p</i> < 0.01), while volume of prostate gland was significantly higher in the BPH group than in PCa (39.1 versus 31.1 cm<sup>3</sup>, <i>p</i> = 0.02).
|
30186533 |
2018 |
Benign Prostatic Hyperplasia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Genome-wide associations for benign prostatic hyperplasia reveal a genetic correlation with serum levels of PSA.
|
30410027 |
2018 |
Benign Prostatic Hyperplasia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The diagnostic efficiency of exosomal ephrinA2 was superior to that of whole serum ephrinA2 and serum PSA in distinguishing PCa patients from those from BPH patents.
|
30087706 |
2018 |
Benign Prostatic Hyperplasia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Receiver-operating characteristic curve (ROC) revealed that miR-145 in UEVs combined with serum PSA could differentiate PCa from BPH better than PSA alone (AUC 0.863 and AUC 0.805, respectively).
|
28617988 |
2017 |
Benign Prostatic Hyperplasia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Insulin was increased and IGFBP-3/PSA was reduced in BPH patients with increased prostate size.
|
28300542 |
2017 |
Benign Prostatic Hyperplasia
|
0.100 |
Biomarker
|
disease |
BEFREE |
With the more sensitive nanoparticle-based lectin-immunoassay we detected a statistically significant increase in the PSA fucosylation in PCa tissue compared to benign tissue (p=0.001) and in urine from PCa patients compared to BPH patients (p=0.030), and an even greater discrimination (p=0.010) when comparing BPH patients to PCa patients with Gleason score≥7.
|
27818346 |
2017 |
Benign Prostatic Hyperplasia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Moreover, the combination of MIC-1 and PSA was allowing 99.1% AUC for the differentiation of BPH + PC from HC, 97.9% AUC for differentiation of BPH from HC, 98.6% AUC for differentiation of PC from HC, and 96.7% AUC for the differentiation of PC from BPH.
|
29203798 |
2017 |
Benign Prostatic Hyperplasia
|
0.100 |
Biomarker
|
disease |
BEFREE |
PSA showed high immunoexpression in all BPH patients and a focal positivity in Ser-Se-Ly treated patients after 3 months.
|
28327526 |
2017 |
Benign Prostatic Hyperplasia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Alterations in expressed prostate secretion-urine PSA N-glycosylation discriminate prostate cancer from benign prostate hyperplasia.
|
29100363 |
2017 |
Benign Prostatic Hyperplasia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
PSA-158G/A polymorphism may be an inhibitor to the incidence of BPH in Caucasians, but it is likely to be a susceptible factor in Asians.
|
28430620 |
2017 |
Benign Prostatic Hyperplasia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Histology of prostate revealed hyperplasia of transition lobe, increased expression of PSA, and Ki67 in BPH.
|
28211173 |
2017 |
Benign Prostatic Hyperplasia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Differential blood-based diagnosis between benign prostatic hyperplasia and prostate cancer: miRNA as source for biomarkers independent of PSA level, Gleason score, or TNM status.
|
26831660 |
2016 |
Benign Prostatic Hyperplasia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Immunostaining, ELISA, and in situ hybridization analyses of BPH tissues verified the presence of PSA protein but absence of PSA mRNA in the stromal compartment.
|
24711254 |
2014 |
Benign Prostatic Hyperplasia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Receiver Operating Curve (ROC) analysis demonstrated that TSP2 transcript levels can better distinguish PCa from BPH tissue samples (P<0.01) than serum PSA levels (P=0.299).
|
23470460 |
2013 |
Benign Prostatic Hyperplasia
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, effects of the 14 SNPs on BPH related clinical traits, including International Prostate Symptom Score (IPSS), prostate volume, total PSA, and free PSA were evaluated using linear regression analysis.
|
23620269 |
2013 |
Benign Prostatic Hyperplasia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our data suggested that circulating miRNAs could serve as biomarkers for CaP, and compared to single miRNA, the 5 miRNAs panel can accurately discriminate CaP from BPH and healthy controls with high sensitivity and specificity, and therefore, combined with routine PSA test, these 5 CaP-specific miRNAs may help improve CaP diagnosis in clinical application.
|
22298030 |
2012 |
Benign Prostatic Hyperplasia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Using quantitative real-time polymerase chain reaction, we found a significant upregulation of AR and PSA mRNA expression in CaP comparison to BPH.
|
22731640 |
2012 |
Benign Prostatic Hyperplasia
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study was to determine whether PSCA mRNA positivity in preoperatively negative prostatic biopsy samples from BPH men with PSA > 4.0 ng/ml and/or suspicious DRE findings had predictive performance following TURP.
|
19462463 |
2009 |
Benign Prostatic Hyperplasia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A novel splice variant of PSA was identified, PSA-SV5, that may be exploited in clinical diagnosis to distinguish prostate cancer from benign prostate hyperplasia.
|
18222179 |
2008 |
Benign Prostatic Hyperplasia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Genetic polymorphism of the ER, CYP17, SRD5A2 (TA repeats), and PSA genes were analyzed in 157 cases of prostate cancer and 340 controls [170 healthy males and 170 patients of benign prostate hyperplasia (BPH)].
|
18722876 |
2008 |